Drugs / TSX-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02222558 | Sep 2014 → Apr 2015 | hypogonadism, male | TesoRx Pharma, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01717768 | Oct 2012 → Aug 2014 | hypogonadism, male | TesoRx Pharma, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSX-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222558 ↗ |
| Route | Oral | “TSX-002, which will be taken orally twice per day for 15 days” NCT01717768 ↗ |